In vitro synergism of fosfomycin and clarithromycin antimicrobials against methicillin-resistant Staphylococcus pseudintermedius

BMC Microbiology

Ameet Singh³  J Scott Weese¹  Suresh Neethirajan²  Matthew DiCicco² 

[1] Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph N1G 2 W1, Canada;BioNano Laboratory, School of Engineering, University of Guelph, Guelph N1G 2 W1, Canada;Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Guelph N1G 2 W1, Canada

关键词: MRSP;    Synergistic effect;    Antimicrobials;    Fosfomycin;    Clarithromycin;    Biofilms;    Staphylococcus;   

Others  :  1141044
DOI  :  10.1186/1471-2180-14-129

 received in 2014-04-15, accepted in 2014-05-14,  发布年份 2014

【 摘 要 】

Background

Bacterial biofilms are of tremendous concern for clinicians, as they can compromise the ability of the immune system and antimicrobial therapy to resolve chronic and recurrent infections. Novel antimicrobial therapies or combinations targeted against biofilm establishment and growth subsequently represent a promising new option for the treatment of chronic infectious diseases. In this study, we treated bacterial biofilms produced by methicillin-resistant Staphylococcus pseudintermedius (MRSP) with a combination of fosfomycin and clarithromycin. We selected these agents, because they prevent biofilm formation and induce antimicrobial synergism that may also target other staphylococci.

Results

We determined that the combination of fosfomycin and clarithromycin better impairs S. pseudintermedius biofilm formation compared to treatment with either therapy alone (P < 0.05). Morphological examination of these biofilms via scanning electron microscopy demonstrated that fosfomycin alone does impact biofilm formation on orthopaedic implants. However, this activity is enhanced in the presence of clarithromycin. We propose that the bacteriostatic activity of clarithromycin is accentuated when fosfoymcin is present, as it may allow better penetration into the biofilm matrix, allowing fosfomycin access to sessile bacteria near the surface of attachment.

Conclusions

Here, we demonstrate that the combination of fosfomycin and clarithromycin may be a useful therapy that could improve the clinical outcomes of treating antimicrobial resistant MRSP biofilms.

【 授权许可】

   
2014 DiCicco et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 2.

Figure 4.

【 参考文献 】

• [1]Beceiro A, Tomas M, Bou G: Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev 2013, 26:185-230.
• [2]Skindersoe ME, Alhede M, Phipps R, Yang L, Jensen PO, Rasmussen TB, Bjarnsholt T, Tolker-Nielsen T, Hoiby N, Givskov M: Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008, 52:3648-3663.
• [3]Falsetta ML, Klein MI, Lemos JA, Silva BB, Agidi S, Scott-Anne KK, Koo H: Novel antibiofilm chemotherapy targets exopolysaccharide synthesis and stress tolerance in streptococcus mutans to modulate virulence expression in vivo. Antimicrob Agents Chemother 2012, 56(12):6201-6211.
• [4]Grif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F: In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 2001, 48:209-217.
• [5]Flemming H, Wingender J: The biofilm matrix. Nat Rev Microbiol 2010, 8:623-633.
• [6]Costerton JW, Stewart PS: Bacterial Biofilms: a common cause of persistent infections. Science 1999, 284:1318-1322.
• [7]Lau WY, Teoh-Chan CH, Fan ST: In vitro and in vivo study of fosfoymcin in methicillin-resistant Staphylococcus aureus. J Hyg 1986, 96:416-423.
• [8]Bjarnshot T, Ciofu O, Molin S, Givskov M, Hoiby N: Applying insights from biofilm biology to drug development - can a new approach be developed? Nat Rev Drug Discov 2013, 12:791-808.
• [9]Fuente-Nunez C, Reffuveille F, Fernandez L, Hancock REW: Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies. Curr Opin Microbiol 2013, 16:1-10.
• [10]Geoghegan JA, Smith EJ, Speziale P, Foster TJ: Staphylococcus pseudintermedius expresses surface proteins that closely resemble those from Staphylococcus aureus. Vet Microbiol 2009, 138:345-352.
• [11]Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A: The calgary Biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999, 37:1771-1776.
• [12]Murayama B, Nagata M, Terada Y, Okuaki M, Takemura N, Nakaminami H, Noguchi N: In vitro antiseptic susceptibilities for Staphylococcus pseudintermedius isolated from canine superficial pyoderma in Japan. Vet Dermatol 2013, 24:126-e29.
• [13]OEGACH: EUCAST breakpoints. 2009. http://www.oegach.at: webcite Austrian Society for Antimicrobial Chemotherapy
• [14]Morikawa K, Nonaka M, Yoshikawa Y, Torii I: Synergistic effect of fosfomycin and arbekacin on a methicillin-resistant staphylococcus aureus-induced biofilm in a rat model. Int J Antimicrob Agents 2005, 25:44-50.
• [15]Goering RV, Morrison D, Al-Doori Z, Edwards GF, Gemmell CG: Usefulness of mec-associated direct repeat unit (dru) typing in the epidemiological analysis of highly clonal methicillin-resistant Staphylococcus aureus in Scotland. Clin Microbiol Infect 2008, 14:964-969.
• [16]Fujimura S, Sato T, Kikuchi T: Efficacy of clarthiromycin plus vancomycin in mice with implant-related infection caused by biofilm-forming Staphylococcus aureus. J Orthop Sci 2009, 14:658-661.
• [17]Fujimura S, Sato T, Mikami T, Kikuchi T, Gomi K, Watanabe A: Combined efficacy of clarithromycin plus cefazolin or vancomycin against Staphylococcus aureus biofilms formed on titanium medical devices. Int J Antimicrob Agents 2008, 32:481-484.
• [18]Osland AM, Vestby LK, Fanuelsen H, Slettemeas JS, Sunde M: Clonal diversity and biofilm-forming ability of methicillin-resistant Staphylococcus pseudintermedius. J Antimicrob Chemother 2012, 67:841-848.
• [19]DiCicco M, Neethirajan S, Singh A, Weese JS: Efficacy of clarithromycin on biofilm formation of methicillin-resistant Staphylococcus pseudintermedius. BMC Vet Res 2012, 8:225. BioMed Central Full Text
• [20]Kumon H, Ono N: Combination effect of fosfoymcin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm. Antimicrob Agents Chemother 1995, 39:1038-1044.
• [21]Kumon H, Tomochika K, Matunaga T: A sandwich cup method for the penetration assay of antimicrobial agents through Pseudomonas exopolysaccharides. Microbiol Immunol 1994, 38:615-619.
• [22]Lewis K: Persister cells: molecular mechanisms related to antibiotic tolerance. Antibiotic resistance. Handb Exp Pharmacol 2011, 211:121-133.
• [23]Hendricks APA, Budzik JM, So-Young O, Schneedind O: Architects at the bacterial surface – sortases and the assembly of pili with isopeptide bonds. Nat Rev Microbiol 2011, 9:166-176.
• [24]Frossard M, Joukhadar C, Erovic BM, Dittrich P, Mrass PE, Van Houte M, Burgmann H, Georgopoulos A, Muller M: Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrob Agents Chemother 2000, 44:2728-2732.
• [25]Sun F, Liang H, Kong X, XIe S, Cho H, Deng X, Ji Q, Zhang H, Alvarex S, Hicks LM, Bae T, Luo C, Jiang H, He C: Quorum-sensing agr mediates bacterial oxidation response via an intramolecular disulfide redox switch in the response regulator AgrA. Proc Natl Acad Sci U S A 2012, 109:9095-9100.
• [26]Fujimura S, Sato T, Kikuchi T, Zaini J, Gomi K, Watanabe A: Efficacy of clarithromycin plus vancomycin in mice with implant-related infection caused by biofilm-forming Staphylococcus aureus. J Orthop Sci 2009, 14:658-661.
• [27]Kahan FM, Kahan JS, Cassidy PJ, Kropp H: The mechanism of action of fosfomycin phosphonomycin). Ann N Y Acad Sci 1974, 235:364-386.
• [28]Kikuchi K, Totsuka K, Shimizu K, Ishii T, Yoshida T, Orikasa Y: Effects of combination of benzylpenicillin and fosfomycin on penicillin-resistant Streptococcus pnemoniae. Microb Drug Resist 1995, 1:185-189.
• [29]Apisarnthanarak A, Mundy LM: Successful treatment of disseminated methicillin-resistant Staphylococcus aureus with fosfomycin, cefoperzone/sulbactam and rifampin followed by fusidic acid and rifampin. Int J Infect Dis 2007, 11:283-284.
• [30]Kono K, Takeda S, Tatara I, Arakawa K, Tanaka H, Miyake S, Minamikawa H, Hoshino H, Sato M, Hattori F: Combined therapy with arbekacin and fosfomycin for methicillin-resistant Staphylococcus aureus infections. Jpn J Antibiot 1994, 47:798-803.
• [31]Reeves DS: Fosfomycin trometamol. J Antimicrob Chemother 1994, 34:853-858.
• [32]Hall-Stoodley L, Costerton JW, Stoodley P: Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004, 2:95-108.
• [33]Garrigós C, Murilloa O, Lora-Tamayoa J, Verdaguer R, Tubau F, Cabellos C, Cabo J, Ariza J: Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2013, 57:606-610.
• [34]Moodley A, Stegger M, Zakour NL, Fitzgerald JR, Guardabassi L: Tandem repeat sequence analysis of staphylococcal protein A (spa) gene in methicillin-resistant Staphylococcus pseudintermedius. Vet Microbiol 2009, 135:320-326.
• [35]Bannoehr J, Zakour NL, Reglinski M, Inglis N: Genomic and surface proteomic analysis of the canine pathogen Staphylococcus pseudintermedius reveals protein that mediate adherence to the extracellular matrix. Infect Immun 2011, 79:3074-3086.
• [36]Mikuniya T, Kato Y, Ida T: Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J Infect Chemother 2007, 13:285-290.
• [37]Parra-Ruiz J, Vidaillac C, Rybak MJ: Macrolides and staphylococcal biofilms. Rev Esp Quimioter 2012, 25:10-16.
• [38]Parsek MR, Greenberg EP: Sociomicrobiology: the connections between quorum sensing and biofilms. Trends Microbiol 2005, 13:27-33.
• [39]Stepanovic S, Vukovic D, Hola V, Di Bonaventura G, Djukic S, Cirkovic I, Ruzicka F: Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS 2007, 115:891-899.
• [40]Bannoehr J, Ben Zakour NL, Waller AS, Guardabassi L, Thoday KL, Broek VAH, Fitzgerald JR: Population genetic structure of the Staphylococcus intermedius group: Insights into agr diversification and the emergence of methicillin-resistant strains. J Bacteriol 2007, 189:8685-8692.
• [41]Sahuquillo Arce JM, Colombo Gainza E, Gil Brusola A, Ortiz Estevez R, Canton E, Gobernado M: In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioter 2006, 19:252-257.
• [42]Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ: Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother 2010, 54:4329-4334.
• [43]Rodríguez-Martínez JM, Ballesta S, Pascual A: Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and co-trimoxazole in Escherichia coli and Pseudomonas aeruginosa biofilms. Int J Antimicrob Agents 2007, 30:366-368.
• [44]Takahashi K, Kanno H: Synergistic activities of combination of beta lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984, 26:789-791.
• [45]Peng HL, Novick RP, Kreiswirth B, Kornblum J, Schlievert P: Cloning, characterization, and sequencing of an accessory gene regulator (agr) in Staphylococcus aureus. J Bacteriol 1988, 170:4365-4372.
• [46]Yamada S, Hyo Y, Ohmori S, Ohuchi M: Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa. Chemotherapy 2007, 53:202-209.
• [47]Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M: A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 2000, 40:175-179.
• [48]Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J: The epidemic of antibiotic-resistant infections: a call to action for the medical community from the infectious diseases society of America. Clin Infect Dis 2008, 46:155-164.
• [49]CLSI: Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement M100-S18. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
• [50]CLSI: Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. In M31-A. Wayne, PA; 2008.
• [51]Gilbert P, Allison DG, McBain AJ: Biofilms in vitro and in vivo: do singular mechanisms imply cross-resistance? Symp Ser Soc Appl Microbiol 2002, 292:98-110.
• [52]Nienhoff U, Kadlec K, Chaberny IF, Verspohl J, Gerlach GF, Kreienbrock L, Schwarz S, Simon D, Nolte I: Methicillin-resistant Staphylococcus pseudintermedius among dogs admitted to a small animal hospital. Vet Microbiol 2011, 150:191-197.
• [53]Cordaro JC, Melton T, Stratis JP, Atagun M, Gladding C, Hartman PE, Roseman S: Fosfomycin resistance: selection method for internal and extended deletions of the phosphoenolpyruvate:sugar phosphotransferase genes of Salmonella typhimurium. J Bacteriol 1976, 128:785-793.
• [54]Gomez-Sanz E, Torres C, Benito D, Lozano C, Zarazaga M: Animal and human staphylococcus aureus associated clonal lineages and high rate of Staphylococcus pseudintermedius novel lineages in Spanish kennel dogs: Predominance of S. aureus ST398. Vet Microbiol 2013, 166:580-589.
• [55]Thauvin C, Lemeland JF, Humbert G, Fillastre JP: Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1988, 32:919-921.